Mesoblast (MESO) has released an update.
Mesoblast Limited, a global leader in allogeneic cellular medicines, announced it will submit a Biologics License Application for its product Ryoncil® to the FDA next week, targeting the treatment of children with steroid-refractory acute graft versus host disease. The company boasts a robust intellectual property portfolio and a range of late-stage product candidates aimed at severe inflammatory conditions. Mesoblast’s off-the-shelf cell therapy products, including remestemcel-L for inflammatory diseases, are poised for rapid availability to patients globally.
For further insights into MESO stock, check out TipRanks’ Stock Analysis page.
